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1124. Acute Kidney Injury Associated with Combination Antimicrobial Therapy 
in the Medical Information Mart for Intensive Care (MIMIC) III Database
W. Cliff Rutter, PharmD, MS and David S. Burgess, PharmD, FCCP; University of 
Kentucky, College of Pharmacy, Lexington, Kentucky
Session: 142. Clinical: Soup to Nuts
Friday, October 6, 2017: 12:30 PM      
Background. Increased acute kidney injury (AKI) incidence is linked with coad-
ministration of vancomycin (VAN) and piperacillin-tazobactam (TZP) in the general 
hospital population when compared with VAN and cefepime (FEP); however, this phe-
nomenon was not found in critically ill patients.
Methods. Patients receiving VAN in combination with FEP or TZP for at least 
48 hours during an intensive care unit stay were included in this retrospective review. 
AKI was defined with the Risk, Injury, Failure, Loss, and End-stage (RIFLE) criteria. 
Exposure to common nephrotoxins was captured within 24 hours of combination 
therapy initiation through the entire treatment window. Basic descriptive statistics 
were performed, along with bivariable and multivariable logistic regression models of 
AKI odds.
Results. In total, 2230 patients were included, with 773 receiving FEP+VAN 
and 1457 receiving TZP+VAN. The groups were well balanced at baseline in most 
covariates, with the exception of hepatorenal syndrome diagnosis (TZP+VAN 1.4% 
vs. FEP+VAN 0.3%, P = 0.02) and vasopressor exposure (TZP+VAN 26.2% vs 21.5%, 
P  =  0.01) being more common in the TZP+VAN group. Patients in the FEP+VAN 
group had a higher underlying severity of disease (Charlson comorbidity index [CCI] 
2.7 vs. 2.3, P =0.0002). AKI incidence was higher in the TZP+VAN cohort (35.1% vs. 
26.5%, P = 0.00004), with each stratification of the RIFLE criteria being higher. The 
time until onset of AKI was similar between groups (TZP+VAN median 1 [0–3] days 
vs. FEP+VAN 1 [0–4] days, P =0.2). After multivariable logistic regression, TZP+VAN 
therapy was associated with an adjust odds ratio (aOR) of AKI of 1.54 (95% confi-
dence interval [CI] 1.25–1.89) compared with FEP+VAN. Other variables associated 
with increased odds of AKI included: age >= 65, duration of antibiotic therapy, higher 
baseline renal function, sepsis, endocarditis, hepatorenal syndrome, thiazide diuretic 
exposure, and increased CCI.
Conclusion. Treatment with TZP+VAN is associated with significant increases in 
AKI incidence among critically ill patients, independent of other risks for AKI.
Disclosures. All authors: No reported disclosures. 
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Background. Acute kidney injury (AKI) is a well-known adverse effect of van-
comycin. Varying degrees and causes of AKI have demonstrated different effects on 
patient outcomes. Since AKI with vancomycin is typically reversible, we investigated 
how AKI associated with vancomycin therapy impacts patient mortality and time to 
discharge.
Methods. Unique patients with methicillin-resistant Staphylococcus aureus 
(MRSA) bacteremia and who received at least one dose of vancomycin were identified 
in a national Veterans Affairs cohort from January 1, 2002 to October 14, 2015. Patients 
with a history of dialysis in the previous year and those with AKI on admission were 
excluded. AKI was defined according to RIFLE criteria, as an increase in serum cre-
atinine (SCr) of 0.5 mg/dL or 1.5× from the admission SCr, on a day they received van-
comycin. Patient characteristics including demographics and comorbidities defined by 
ICD9 codes were compared between groups. Effect estimates for inpatient mortality 
were determined with a backward stepwise logistic regression model in SAS 9.2. For 
patients without inpatient mortality, time to discharge was analyzed using Wilcoxon 
rank-sum test.
Results. There were 7691 included patients with MRSA bacteremia, and 23.8% 
(n = 1830) developed AKI during therapy. Mean age was 66.7 (±12) years and 97.8% (n 
= 7525) were male. Patients with AKI were more likely to have congestive heart failure, 
diabetes, chronic kidney disease, and to be admitted to the intensive care unit (all P < 
0.001). Overall inpatient mortality was 17.7% (n = 1361). The crude odds of inpatient 
mortality were 67% higher in patients with AKI. In the adjusted model, AKI was an 
independent predictor of mortality (OR 1.19, 95% CI 1.02–1.40, P < 0.03). Median 
(IQR) time to discharge was 11 (6–19) days without AKI and 18 (11–31) days with 
AKI (P < 0.0001).
Conclusion. Vancomycin-associated AKI is associated with increased inpatient 
mortality and longer time to discharge. Further research is needed to compare clinical 
outcomes for other groups of patients, and to determine the impact of monitoring 
interventions to improve safety and decrease AKI.
Disclosures. A. Caffrey, Merck: Grant Investigator, Grant recipient The Medicines 
Company: Grant Investigator, Grant recipient Pfizer: Grant Investigator, Grant recipi-
ent K. LaPlante, Merck: Grant Investigator, Grant recipient Pfizer: Grant Investigator, 
Grant recipient Cempra: Scientific Advisor, Consulting fee The Medicines Company: 
Grant Investigator, Grant recipient Allergan: Scientific Advisor, Consulting fee Bard/ 
Davol: Scientific Advisor, Consulting fee Ocean Spray: Grant Investigator and Scientific 
Advisor, Consulting fee and Grant recipient Zavante: Scientific Advisor, Consulting fee 
Achaogen: Scientific Advisor, Consulting fee 
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Background. Despite recommendations against screening urine for bacteri-
uria prior to non-urological surgery, it is still a common practice. If the urine culture 
(Ucx) is positive, clinicians often feel compelled to give targeted therapy or expand the 
peri-operative prophylaxis (PPX) regimen to cover the urinary organism. Large multi-
center studies are lacking. We aimed to evaluate rates and results of preoperative urine 
screening and postoperative outcomes among a national cohort of surgical patients.
Methods. All patients who underwent cardiac, orthopedic implant, or vascular 
surgery within the national VA health care system during the period from 10/1/08–
9/30/13 and had the PPX regimen manually validated were included. Rates of posi-
tive Ucx and wound cultures during the 90-day post-operative period were compared 
between patients with and without pre-operative bacteriuria. Among patients with a 
positive pre-op urine culture the association between activity of surgical PPX and pos-
itive post-op cultures was evaluated.
Results. N = 78,810 surgeries were evaluated (21,889 cardiac, 46,565 orthopedic 
implant, 10,356 vascular). A pre-op Ucx was performed in 26% (Fig); of these, 6.6% 
were positive and 852 (63%) received PPX active against the uropathogen. Positive 
pre-op Ucx was associated with higher rates of positive post-op Ucx and wound cul-
tures (Fig). Among patients who received active PPX, post-op Ucx was positive in 46% 
compared with 39% who received inactive PPX. The rate of post-op wound cultures 
was not different between patients who received active (25%) vs. inactive (24%) PPX. 
The pre-op and post-op organisms were the same in 117/221 (52.9%) Ucx and 17/104 
(16.3%) wound cultures, respectively. PPX activity did not affect the match rate.
Conclusion. This is the largest, multicenter study demonstrating no difference in 
post-op urine and wound cultures in patients receiving active vs. inactive surgical PPX 
for pre-op bacteriuria. Prevalence of bacteriuria was similar to other surgical popula-
tions. Limitations include predominantly male population and need for further char-
acterization of pre-op antibiotic therapy and UTI and SSI outcomes.
Disclosures. All authors: No reported disclosures. 
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Background. Urinary tract infections (UTIs) are common among hospitalized 
patients with 10–40% of cases complicated by bacteremia. Recent literature suggests 
limited utility in repeating blood cultures for non-Staphylococcus aureus bacteremia; 
however, clinicians often repeat blood cultures to document clearance prior to select-
ing definitive therapy for bacteremias. Additionally, comparative data evaluating treat-
ment duration for bacteremic UTIs are lacking and clinical practice guidelines do not 
address optimal duration for bacteremic UTIs. We aimed to evaluate local practice 
patterns and utility of repeat blood cultures and their influence on treatment durations 
for bacteremic UTIs.
Methods. We identified patients with bacteremia from a urinary source at the Salt 
Lake City Veterans Affairs (VA) hospital from a previously compiled cohort of inpa-
tients with bacteremia from any source between November 2013 and October 2015. 
